Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Multi-proteomic analyses provide evidence for origin of a co-existing serum monoclonal gammopathy in CLL/MBL

View Full Paper
Ask AI
Bookmark
Share

Authors

USUday Aditya SarkarMMMariia MikhalevaNONatalie Onofri

Discussion

Loading...

Member takes

Overview

Analysis demonstrates serum monoclonal components in CLL patients, highlighting implications for MGUS identification.

Key Points

  • Up to 78.6% of cases showed identity between serum Ig proteins and those expressed by clonal B cells, indicating robust association.
  • In 3127 patients assessed at the Dana-Farber Cancer Institute, 21% presented with a detectable monoclonal component in serum.
  • Patient samples analyzed using multi-proteomics techniques including MALDI-TOF MS and high-resolution quantitative proteomics.
  • Findings suggest potential pathways of B cell maturation contributing to monoclonal gammopathy in CLL.

Cite This Study

Sarkar et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d91fhttps://doi.org/10.1182/blood-2025-7408
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mass spectrometry-based screening for monoclonal gammopathy in individuals undergoing physical examinations: Analyses of consecutive 15,068 cases in China2025
  2. 2Acquisition of CLL-like epigenetic and transcriptomic states in low-count MBL2025
  3. 3Mass Spectrometric Exploration of Biclonal Gammopathy: Insights from a Diagnostic Laboratory2025
  4. 4Monoclonal gammopathy defines distinct clinical subsets in Chronic Lymphocytic Leukemia across therapeutic eras2025
  5. 5Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial2025